McKesson Corporation (LON:0JZU)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 64.68B |
| Revenue (ttm) | 275.24B |
| Net Income (ttm) | 2.26B |
| Shares Out | n/a |
| EPS (ttm) | 17.43 |
| PE Ratio | 28.65 |
| Forward PE | n/a |
| Dividend | 2.15 (0.32%) |
| Ex-Dividend Date | Mar 3, 2025 |
| Volume | 68 |
| Average Volume | 2,732 |
| Open | 665.96 |
| Previous Close | 660.47 |
| Day's Range | 659.42 - 670.00 |
| 52-Week Range | 335.28 - 670.00 |
| Beta | 0.51 |
| RSI | 65.48 |
| Earnings Date | May 9, 2025 |
About McKesson
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty ... [Read more]
Financial Performance
In 2023, McKesson's revenue was $308.95 billion, an increase of 11.65% compared to the previous year's $276.71 billion. Earnings were $3.00 billion, a decrease of -15.67%.
Financial numbers in USD Financial StatementsNews
McKesson: Immune To Weak Economy And Tariffs; Top Idea In 2025
I maintain a 'Strong Buy' rating on McKesson with a fair value of $723 per share due to its robust oncology network and strong growth prospects. McKesson's minimal exposure to US-Mexico-Canada tariffs...
Trade Tracker: Joe Terranova buys Interactive Brokers and McKesson, sells CVS
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest portfolio moves.
Trade Tracker: Joe Terranova buys Interactive Brokers and McKesson, sells CVS
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest portfolio moves.
McKesson (MCK) and Visa (V) Are 2 Dividend Growth Stocks to Buy For a Lifetime of Passive Income
Investing in dividend growth stocks is a smart, reliable way to build passive income that lasts a lifetime, and it’s worth considering if you’re eyeing financial freedom. These are companies that have...
McKesson Keeps Growing, Eyeing Bigger Future
Health care product distributor McKesson Corporation (MCK) reports big earnings gains, eye care acquisition.
McKesson Corporation (MCK) TD Cowen 45th Annual Healthcare Conference Transcript
These 12 stocks could be big winners if they make this one key move
Stock splits make companies more attractive investments and boost share prices. Here's how to find likely candidates.
Here's How Much You Would Have Made Owning McKesson Stock In The Last 5 Years
McKesson (NYSE: MCK) has outperformed the market over the past 5 years by 15.45% on an annualized basis producing an average annual return of 28.27%. Currently, McKesson has a market capitalization o...
Peering Into McKesson's Recent Short Interest
McKesson's (NYSE: MCK) short percent of float has fallen 7.14% since its last report. The company recently reported that it has 1.49 million shares sold short , which is 1.17% of all regular shares t...
McKesson (MCK) Stock Dips Amidst Market Fluctuations
McKesson (MCK) Stock Dips Amidst Market Fluctuations
Florida Rep. Byron Donalds Bought Over $7K Worth of First Citizens BancShares Stock: Here's What You Should Know
An official report on February 10, 2025 reveals Representative Byron Donalds's recent purchase of First Citizens BancShares (NASDAQ: FCNCA) stock, valued between $7,007 and $105,000. The transaction ...
$100 Invested In McKesson 20 Years Ago Would Be Worth This Much Today
McKesson (NYSE: MCK) has outperformed the market over the past 20 years by 6.52% on an annualized basis producing an average annual return of 14.92%. Currently, McKesson has a market capitalization o...
Decoding McKesson's Options Activity: What's the Big Picture?
Deep-pocketed investors have adopted a bearish approach towards McKesson (NYSE: MCK), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled t...
McKesson, AmerisourceBergen get judge to toss price-fixing lawsuit
A federal judge in Pennsylvania dismisses lawsuit accusing drug distributors of conspiring to raise generic drug prices. Read more here.
McKesson (MCK) Q3 2025 Earnings Call Transcript
MCK earnings call for the period ending December 31, 2024.
McKesson Corporation 2025 Q3 - Results - Earnings Call Presentation
The following slide deck was published by McKesson Corporation in conjunction with their 2025 Q3 earnings call.
McKesson projects $32.55-$32.95 adjusted EPS for FY25, driven by specialty growth
McKesson Corporation (MCK) Q3 2025 Earnings Call Transcript
McKesson misses third-quarter revenue estimates
Drug distributor McKesson missed estimates for third-quarter revenue on Wednesday, hurt by less-than-expected sales in its U.S. pharmaceutical segment, which includes branded and specialty drugs.
McKesson Exceeds EPS, Q3 Profit Surges
McKesson delivered an earnings beat in its latest quarter while slightly missing its revenue target.
McKesson falls 3% on quarterly revenue miss, narrowed fiscal 2025 EPS outlook
McKesson Non-GAAP EPS of $8.03 beats by $0.04, revenue of $95.29B misses by $570M
McKesson Corporation Reports Fiscal 2025 Third Quarter Results and Raises Full Year Adjusted EPS Guidance
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2025 third quarter financial results. Results can be accessed on McKesson's Investor Relations website at inves...
McKesson Q3 2025 Earnings Preview
McKesson (MCK) is set to announce Q3 earnings on February 5th.
McKesson to Acquire 80% Stake in PRISM Vision Holdings for $850 Million
McKesson to Acquire 80% Stake in PRISM Vision Holdings for $850 Million